PARP1 and neoplasm: Moreover, the use of DSF/Cu2+ in conjunction with an anti-PD-1 antibody which jointly inhibits both PARP1 and the PD-1/PD-L1 pathway, not only resulted in reduced tumor cell viability but also led to an increase in the number of T cells that infiltrate the tumor.